Columnist Lisa Weber and her dog Tebow are the perfect match
If a dog could have Raynaud’s phenomenon, my Tebow would be the one to have it. His tiny frame has the thinnest white coat that barely covers him. His pink skin is visible through his fur. And, like me, he’s always seeking out warm spots to cuddle up in.
Sometimes I can’t find him because he’s wedged himself between the pillows on the couch. I get it, though. I always cover myself in blankets and socks when I’m lounging around.
The therapy's effectiveness is being tested in a Phase 2 clinical trial
By Somi Igbene, PhD
The experimental therapy MT-7117 reduces lung inflammation, skin fibrosis (scarring), and blood vessel impairment in a mouse model of systemic sclerosis (SSc), a study found.
“MT-7117 demonstrates disease-modifying effects in preclinical models of SSc,” the researchers wrote. “The results of the present study suggest that MT-7117 is a potential therapeutic agent for SSc.”
ILD first found in 4% to 6% of scleroderma patients in US claims database
Practicing meditation helps columnist Lisa Weber reduce the stress in her life.
Levels of the protein were higher in patients with diastolic, autonomic dysfunction.
Kedron-Wavell Services Club has generously provided a community donation of $300 for the cost of room hire for our event with Associate Professor Tony Kenna in September.
Generous donations such as this from #kw allows Scleroderma Queensland to raise such important funds for much-needed research and awareness.
THANK YOU AGAIN to Kedron-Wavell Services Club. We gratefully acknowledge their support.
#KW #KedronWavell #eventsatkw
Patient stem cells offer a promising way to test potential therapies for rare diseases
The investigational oral therapy APT-101 was well tolerated and reduced fibrosis, or scarring, in a mouse model of systemic sclerosis (SSc), according to a recent presentation from the therapy’s developer, Apie Therapeutics.
How many times have you asked yourself, “Is this scleroderma?” Odd sensations, abnormal changes, pain, and even visible deformities — there’s no shortage of strange symptoms with this disease.
I used to embark on a fruitless journey to discover answers, spending hours researching and probing fellow patients in support groups. I never found answers that helped. I only found people experiencing the same thing, but not an explanation for why it was happening. Nothing I discovered helped to stop the pain or heal the damage.
About 2% of people with scleroderma are positive for more than one disease-associated antibody that targets tissues, causing damaging inflammation, according to a new study.
Results suggest that certain antibody combinations may be associated with distinct clinical features.
Scleroderma Queensland Support Group